Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine for Mild Symptomatic and Asymptomatic COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18~* A person diagnosed with COVID-19 in the past 48 hours~* Asymptomatic~Exclusion Criteria:~* chronic lung disease with chronic hypoxia~* Sleep apnea requiring BIPAP / continuous positive airway pressure~* Retinal disease~* Porphyria~* Myastenia gravis~* immunodeficiency disorders~* Hearing Disorders~* Scheduled for general anesthesia~* treatment with antibiotics or antiretroviral for any reason~* Pulse \<50~* Known Ventricular arrhythmias~* Heart Failure: Systolic or Diastolic~* kown QT prolongation~* Taking medicines that increase the risk of QT prolongation in combination with CHLOROQUINE.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- low dose chloroquine (Type: EXPERIMENTAL): oral chloroquine 125mg daily for 7 days (or until the condition worsens, whichever comes first)
- Regular dose chloroquine (Type: EXPERIMENTAL): oral chloroquine 500 mg twice daily for 7 days (or until the condition worsens, whichever comes first)
- Standard of care (Type: OTHER): The treatment is mostly supportive in character and is given, based on patient's clinical state. Antibiotics do not help patients fight novel coronavirus.

Based on this trial design, predict the completion outcome and termination type (if applicable).